15:17 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression....
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
12:32 , Feb 27, 2018 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
17:09 , Feb 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest inhibiting PERK or IRE1 could help prevent embryonic microcephaly caused by Zika infection. In a mouse embryo model of Zika infection, tool compound PERK or IRE1 inhibitors decreased microcephaly...
18:24 , Jun 22, 2017 |  BC Innovations  |  Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send...
07:00 , Jun 5, 2014 |  BC Innovations  |  Targets & Mechanisms

De-stressing glaucoma

Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Eukaryotic translation initiation factor 2a kinase 3 (EIF2AK3; PERK) Primary tumor, cell culture and mouse studies suggest PERK inhibitors could help treat breast...
08:00 , Feb 13, 2014 |  BC Innovations  |  Tools & Techniques

Micromanaging the microenvironment

A Massachusetts team has designed an in vivo shRNA screen to discover immunosuppressive tumor targets that can be blocked to improve the efficacy of T cell immunotherapies. 1 The screening system shows that current checkpoint...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Eukaryotic translation initiation factor 2a kinase 3 (EIF2AK3; PERK); TAR DNA binding protein 43 (TDP-43; TARDBP) Studies in flies and primary...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Calcium calmodulin-dependent protein kinase IIg (CAMK2G) Mouse studies suggest inhibiting CAMK2G could help improve hyperglycemia and insulin sensitivity in patients with type 2...